youtube_live
Q1 2026 daromadi • Bugun, 5:00 PM
Tafsilotlarchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
24,81 US$
arrow_upward
+0,16%(+0,040) 1K
24,81 US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 4-may, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoRARE tikeri uchun statistika yaratilmoqda...
Ochish
24,69 US$
Yuqori
25,32 US$
Past
24,49 US$
Bozor kapitali
2,44 mlrd
Oʻrtacha hajm
1,96 mln
Hajmi
0,00
52 haftalik eng yuqori
42,37 US$
52 haftalik eng past
18,29 US$
Aksiya boʻyicha daromad
-5,83 US$
Beta
0,39
Muomaladagi aksiyalar
98,32 mln
Xodimlar soni
1 ming
Yangiliklar
Internetdagi manbalardan
TipRanks
·
2 soat oldin
Ultragenyx CFO’s Latest Stock Move Has Investors Buzzing
MarketBeat
·
5 soat oldin
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 Shares
Investing.com
·
7 soat oldin
Ultragenyx CFO Howard Horn sells $116,606 in company stock
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc haqida
CEOEmil Kakkis
Xodimlar soni1,37 ming
Asos solingan2010
Bosh ofislarNovato, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytultragenyx.com
AI kontentda xatolar boʻlishi mumkin. Batafsil